title: Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients.
abstract: Postoperative diabetes is a reported feature of the immunosuppressive agents cyclosporin A and FK 506. To date, however, no randomized comparative studies of the metabolic effects of these two drugs have been performed. In this study, extended (300 min) oral glucose tolerance tests (75 g) were performed a median of 8 mo (range 5-9 mo) postoperatively in 20 clinically stable liver transplant recipients randomly allocated to maintenance immunosuppression with either cyclosporin A (with or without azathioprine) or FK 506. None of the patients had clinically overt diabetes antedating transplantation. To avoid the confounding effects of corticosteroids, prednisolone was withdrawn at least 6 wk beforehand in each case. Ten healthy volunteers matched for age and body mass index served as control subjects. Overall blood glucose concentrations after the glucose challenge were significantly elevated in both groups of transplant recipients (P < 0.005 and P < 0.001 for cyclosporin A and FK 506 treatment groups, respectively) compared with the healthy control subjects. Venous whole-blood glucose concentration (mean +/- SE) 120 min after the ingestion of oral glucose was significantly higher in both the cyclosporin A (P < 0.05) and FK 506 (P < 0.01) treatment groups compared with the control subjects (6.6 +/- 0.5 vs. 8.8 +/- 0.9 vs. 5.2 +/- 0.2 mM, respectively). According to 1985 WHO criteria, 4 of 10 cyclosporin A-treated patients had impaired glucose tolerance, whereas 3 of 10 FK 506-treated patients had diabetes with 4 others having impaired glucose tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Diabetic Clinic, General Hospital, Birmingham, United Kingdom.
authors.forename: A J
authors.initials: AJ
authors.lastname: Krentz
authors.forename: B
authors.initials: B
authors.lastname: Dousset
authors.forename: D
authors.initials: D
authors.lastname: Mayer
authors.forename: P
authors.initials: P
authors.lastname: McMaster
authors.forename: J
authors.initials: J
authors.lastname: Buckels
authors.forename: R
authors.initials: R
authors.lastname: Cramb
authors.forename: J M
authors.initials: JM
authors.lastname: Smith
authors.forename: M
authors.initials: M
authors.lastname: Nattrass
mesh_terms: D000704:Analysis of Variance; D001379:Azathioprine / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D005990:Glycerol / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood*; D007657:Ketone Bodies / Q000097:blood; D007773:Lactates / Q000097:blood; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011773:Pyruvates / Q000097:blood; D019289:Pyruvic Acid; D012016:Reference Values; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D007657:Ketone Bodies; D007773:Lactates; D011773:Pyruvates; D016572:Cyclosporine; D019289:Pyruvic Acid; D001379:Azathioprine; D005990:Glycerol; D016559:Tacrolimus